A Phase 1, Randomized, Placebo-controlled, Double Blind, Single, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ANX005 Monotherapy and ANX005 in Combination With IVIg in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2017
At a glance
- Drugs ANX 005 (Primary)
- Indications Autoimmune disorders; CNS disorders
- Focus Adverse reactions
- Sponsors Annexon
- 03 Jan 2017 Status changed from planning to recruiting.
- 03 Oct 2016 New trial record
- 19 Sep 2016 According to Annexon Biosciences media release, company plans to initiate this study in 2017.